Zuranolone

Zuranolone
Clinical data
Pronunciation/zʊˈrænəln/
zuu-RAN-ə-lohn
Trade namesZurzuvae
Other namesSAGE-217; S-812217; SGE-797; BIIB-125
AHFS/Drugs.comMonograph
MedlinePlusa623048
License data
Pregnancy
category
  • Contraindicated
Routes of
administration
By mouth
Drug classNeurosteroid; GABAA receptor positive allosteric modulator
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding99.5%
MetabolismCYP3A4
Elimination half-life16–23 hours
Identifiers
  • 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.271.331
Chemical and physical data
FormulaC25H35N3O2
Molar mass409.574 g·mol−1
3D model (JSmol)
  • O=C(CN1N=CC(C#N)=C1)[C@H]2CC[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@](C)(O)CC[C@]5([H])[C@@]4([H])CC[C@@]32C
  • InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
  • Key:HARRKNSQXBRBGZ-GVKWWOCJSA-N

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. It is taken by mouth. Zuranolone is a neuroactive steroid which enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA) and is thought to exert antidepressant effects by enhancing GABAergic inhibition.

The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.

Zuranolone was approved for medical use in the United States for the treatment of postpartum depression in August 2023. It was developed by Sage Therapeutics and Biogen.